In today’s recent session, 0.44 million shares of the Summit Therapeutics Inc (NASDAQ:SMMT) have been traded, and its beta is -0.91. Most recently the company’s share price was $18.90, and it changed around $0.59 or 3.19% from the last close, which brings the market valuation of the company to $13.93B. SMMT at last check was trading at a discount to its 52-week high of $33.89, offering almost -79.31% off that amount. The share price’s 52-week low was $1.84, which indicates that the recent value has risen by an impressive 90.26% since then. We note from Summit Therapeutics Inc’s average daily trading volume that its 10-day average is 1.96 million shares, with the 3-month average coming to 5.08 million.
Summit Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended SMMT as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Summit Therapeutics Inc is expected to report earnings per share of -0.06 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Instantly SMMT has been showing a green trend so far today with a performance of 3.19% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 22.25 on recent trading dayincreased the stock’s daily price by 15.06%. The company’s shares are currently up 623.95% year-to-date, but still down -13.21% over the last five days. On the other hand, Summit Therapeutics Inc (NASDAQ:SMMT) is -10.91% down in the 30-day period. We can see from the shorts that 17.04 million shares have been sold at a short interest cover period of 5.67 day(s).
The consensus price target as assigned by Wall Street analysts is $36, which translates to bulls needing to increase their stock price by 47.5% from its current value. Analyst projections state that SMMT is forecast to be at a low of $23 and a high of $45.
Summit Therapeutics Inc (SMMT) estimates and forecasts
Summit Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 316.19 percent over the past six months and at a -130.77% annual growth rate that is well below the industry average of 15.60%.
Forecasts for the next quarter put sales growth at �.
SMMT Dividends
Summit Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-18.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 84.36% of Summit Therapeutics Inc shares, and 11.75% of them are in the hands of institutional investors. The stock currently has a share float of 75.15%. Summit Therapeutics Inc stock is held by 224.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 3.309% of the shares, which is about 23.22 million shares worth $181.13 million.
VANGUARD GROUP INC, with 1.2566% or 8.82 million shares worth $68.78 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
